>
Iran Is Watching Its Economy Collapse in Real Time
California's New Tire Rule will Result in Higher Costs and More Highway Deaths
Covid Was a Praxeological Test. Too Many Libertarians Failed.
This Is What A "Perfect Storm" Looks Like:
Tesla Model 3 killer charges from 10 to 97% in just 9 minutes
World-first unpowered DNA computer sets speed record
I Power 5 Buildings Off-Grid. Here's How
The US government is pushing hard to get a working nuclear fission reactor into space by late 2028
SpaceX Starmind AI in Space Radiator
China Will Dominate Global Nuclear Energy Through 2035, Analyst Says
These Absolutely Wild-Looking EVs Are Saudi Arabia's First Homegrown Cars
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal

Like the horse of Troy, scientists at the Technion have developed a way to sneak synthetic cells right into tumor tissue, where they then begin producing cancer-fighting proteins from the inside. The technique was tested in both cell cultures and in mice, and found to be an effective treatment in both cases.
Cancer cells thrive thanks to some robust defense mechanisms, so finding ways to get past them is a key area of research. In the past, scientists have sent gold nanoparticles inside tumors by hitchhiking on white blood cells, before heating the gold with near-infrared light to kill the cancer from within. Others examined the possibility of administering a "prodrug" that remained inactive until it detected cancer markers, and then began producing drugs from inside the tumor.
The new work follows a similar function as the latter. The Technion scientists loaded molecular machines inside lipid-based particles that resemble biological cell membranes, creating what they call "nano-factories." Once they're activated by sensing the presence of abnormal cells, these particles kick into gear, producing specific therapeutic proteins and pulling the energy and building blocks they need from the tumor tissue around them.
"By coding the integrated DNA template, the particles we developed can produce a variety of protein medicines," says Avi Schroeder, one of the lead researchers on the study. "They are modular, meaning they allow for activation of protein production in accordance with the environmental conditions. Therefore, the artificial cells we've developed at the Technion may take an important part in the personalized medicine trend – adjustment of treatment to the genetic and medical profile of a specific patient."